BlackRock, Inc.

BlackRock’s 2026 10-Q, filed May 6, 2026, offers a detailed look into the company’s self-assessed financial exposures, particularly within its investment portfolio. The Management’s Discussion and Analysis (MD&A) in Item 7 specifically quantifies the net exposure to equity market price risk at approximately $1.2 billion as of March 31, 2026. This exposure, encompassing public and private equity, real assets, and various funds, is further clarified by an estimate that a hypothetical 10% adverse change in market prices would decrease the carrying value of these investments by $124 million. Such disclosures provide a direct measure of the company’s sensitivity to market volatility.

This filing, notably, does not provide the inputs necessary to calculate several standard forensic metrics. Consequently, the Beneish M-Score — Beneish’s 1999 eight-ratio earnings-manipulation detector — is not available. Similarly, Altman’s Z″ — a 1968 bankruptcy-distress index — cannot be computed from the provided excerpts. The Piotroski F-Score, a 9-point fundamental strength scan, is also unavailable, as is the Fog Index — a readability score where 12 equals a newspaper and 18+ is obfuscatory. The absence of these calculated scores means this particular reading cannot comment on their specific signals for financial health or disclosure clarity.

Delving further into Item 7, the MD&A highlights additional sensitivities beyond equity markets. The company reports an exposure to interest rate risk and credit spread risk from approximately $3.7 billion in debt securities as of March 31, 2026. This quantification of risk, alongside the equity market price risk, provides a granular view of how BlackRock’s investment portfolio could be affected by shifts in broader financial conditions. The company’s consolidated statements of financial condition also show $9.841 billion in cash and cash equivalents and $14.574 billion in investments at March 31, 2026.

While this filing offers specific insights into BlackRock’s financial condition and its quantified market exposures, it does not, by itself, determine whether the security is mispriced. The detailed risk assessments in the MD&A provide a framework for understanding potential impacts on the company’s investment portfolio, but the absence of calculated forensic scores in this reading limits a deeper, ratio-based analysis of earnings quality or bankruptcy risk. A comprehensive valuation would require additional data and a broader market perspective.